利用监测、流行病学和最终结果项目数据库,2015年至2020年肺癌、乳腺癌、结直肠癌和前列腺癌的治疗起始时间及其影响因素

IF 2.1 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2025-04-01 Epub Date: 2025-02-25 DOI:10.14740/wjon2519
Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias
{"title":"利用监测、流行病学和最终结果项目数据库,2015年至2020年肺癌、乳腺癌、结直肠癌和前列腺癌的治疗起始时间及其影响因素","authors":"Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias","doi":"10.14740/wjon2519","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.</p><p><strong>Methods: </strong>We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.</p><p><strong>Results: </strong>Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.</p><p><strong>Conclusion: </strong>Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 2","pages":"152-160"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954607/pdf/","citationCount":"0","resultStr":"{\"title\":\"Time to Treatment Initiation of Lung, Breast, Colorectal, and Prostate Cancers and Contributing Factors From 2015 to 2020 Utilizing Surveillance, Epidemiology, and End Results Program Database.\",\"authors\":\"Mariela Di Vanna, Shreya Shambhavi, Murod Khikmatov, Song Peng Ang, Jose Iglesias\",\"doi\":\"10.14740/wjon2519\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.</p><p><strong>Methods: </strong>We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.</p><p><strong>Results: </strong>Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.</p><p><strong>Conclusion: </strong>Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.</p>\",\"PeriodicalId\":46797,\"journal\":{\"name\":\"World Journal of Oncology\",\"volume\":\"16 2\",\"pages\":\"152-160\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954607/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/wjon2519\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:本研究的目的是确定导致延迟开始治疗的因素,如种族、性别、教育程度、收入状况和相关的健康合并症,因为这些因素会增加死亡率。方法:我们利用监测、流行病学和最终结果(SEER)数据库,确定2015年至2020年991,772例肺癌、乳腺癌、结直肠癌(CRC)和前列腺癌患者从诊断到治疗开始(TTI)时间的影响因素,如社会人口统计学。研究的变量包括年龄、性别、种族、婚姻状况、地理位置、家庭收入、阶段和年级。采用双向方差分析(ANOVA)来确定相对于变量,对TTI的影响之间是否存在显著差异。TTI以月为单位测量。基于上述变量,对诊断后超过1个月接受晚期治疗的几率进行倾向评分。患者1:1配对。基于倾向评分,采用竞争风险回归模型确定与晚期治疗相关的危险因素。结果:在所有癌症中都有类似的趋势。就性别而言,在乳腺癌中,男性的TTI(1.02个月)短于女性的1.24个月(P < 0.001)。65岁以上肺癌患者的TTI时间更长(1.38个月,P < 0.001)。在白人患者的所有癌症中,TTI明显较短(P < 0.001)。已婚患者与丧偶、离婚或单身患者相比,TTI时间更短。在所有癌症中,低收入和非大都市地区的患者TTI较短。侵袭性癌症的TTI较短。倾向匹配竞争风险风险分析显示,年轻患者、居住在大都市地区的患者、收入超过3.5万美元的患者以及局部和分化良好的癌症患者延迟治疗超过1个月的风险更大。结论:健康差距今天仍然存在,这在我们的研究中变得更加明显,因为年龄、性别和种族,以及其他因素,可能导致从癌症诊断到治疗开始的时间延迟,可能对这些人群的生存产生负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Time to Treatment Initiation of Lung, Breast, Colorectal, and Prostate Cancers and Contributing Factors From 2015 to 2020 Utilizing Surveillance, Epidemiology, and End Results Program Database.

Background: The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality.

Methods: We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify contributing factors such as sociodemographics that impact time from diagnosis to treatment initiation (TTI) in lung cancer, breast cancer, colorectal cancer (CRC) and prostate cancer from 2015 to 2020 in 991,772 patients. Variables studied included age, sex, race, marital status, geographic location, household income, stage, and grade. Two-way analysis of variance (ANOVA) was utilized to determine if significant differences existed between the effects on TTI with respect to the variables. TTI was measured in months. Based on the aforementioned variables, propensity scores were created for odds of receiving late treatment exceeding 1 month from diagnosis. Patients were matched 1:1. Based on the propensity score, a competing risk regression model was utilized to determine risk factors associated with late treatment.

Results: Similar trends were noted among all cancers. With respect to gender, in breast cancer, TTI was shorter in males (1.02 months) compared to females at 1.24 (P < 0.001). A longer time to TTI was noted in patients greater than 65 years with lung cancer (1.38 months, P < 0.001). Shorter TTI was evident across all cancers for White patients (P < 0.001). Shorter TTI was noted among married versus widowed, divorced, or single patients. Patients with lower income and non-metropolitan regions had shorter TTI among all cancers. More aggressive cancers had shorter TTI. Propensity matched competing risks hazard analysis revealed similar results with younger patients, those living in metropolitan regions, those earning greater than $35,000, and localized and well-differentiated cancers being at greater risk of having a treatment delay greater than 1 month.

Conclusion: Health disparities still exist today, and this becomes more evident in our study as age, sex, and race, among other factors, can cause delays in time from diagnosis of cancer to treatment initiation, potentially negatively affecting survival in these populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信